Veliparib (ABT-888)

For research use only. Not for use in humans.

目录号:S1004 别名: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1277.12 现货
RMB 973.01 现货
RMB 3010.72 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Veliparib (ABT-888)发表文献119篇:

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Phase 3。
特性 ABT-888增强常见癌症疗法的效果,比如放射疗法和烷基化剂。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
体外研究

ABT-888有效抑制PARP,作用于PARP-1和PARP-2时Ki值分别为5.2和2.9 nM。ABT-888降低肺癌H460细胞中克隆基因的存活率,且抑制DNA修复。[1]ABT-888抑制C41细胞,EC50为2 nM。[2] ABT-888和放射物联用减少肿瘤血管的形成。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NX;YPWJqU2mwYYPlJGF{e2G7 MVqzNEBucW5? MUDJcohq[mm2aX;uJI9nKFCDUmCxJJdqfGhiRVO1NEBw\iByLkCwNkDPxE1? MWWxPVg5QDd4MB?=
Jurkat NVHHPIVIU2mwYYPlJGF{e2G7 M1\CZVk3KGh? MUTEUXNQ NUTQ[4RpUW6qaXLpeIlwdiCxZjDQRXJROSCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImge4l1cCCHQ{WwJI9nKDNizszN NV;5S|hOOjN6NUCxPVk>
Capan1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorKO|IhcA>? NH;HZoVFVVOR Mon6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? NUTvXXNkOjR|OUizPFM>
DT40 NYLtcYdbS3m2b4TvfIlkKEG|c3H5 NWm2SFJzPzJiaB?= NYD4eZE1TE2VTx?= NI\ZWldEgXSxdH;4bYNqfHliYXfhbY5{fCClaHnjb4VvKEKUQ1GyMYRm\mmlaXXueEBFXDRyIHPlcIx{ NFfHVIQzPDl{MkW4Oy=>
ML-1 Mlm3RZBweHSxdHnjJGF{e2G7 NE\sNm8zNjVizszN M1TCe|I1KGh? M4nwNmROW09? MlfJV5lv\XKpaYP0bYNidGy7IHXubIFv[2W|IGTSRWlNNWmwZIXj[YQh[XCxcITvd4l{KGmwIF3MMVEh[2WubIO= NIf2OGIzPDh7NUGzOS=>
HCT-116 MVvLbY5ie2ViQYPzZZk> MYmwMlUh|ryP M1LBOVI1KGh? MoPsVGFTWCCjY4Tpeol1gSCmZXPy[YF{\XN? MkXyNlMxPTR{MUO=
UM-SCC1 M1;2UGN6fG:2b4jpZ{BCe3OjeR?= NULPTllMOTBizszN NF3YenozPCCq MWfS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= M3[x[|IyQTF{NkKw
FaDu NY\1UZp{S3m2b4TvfIlkKEG|c3H5 NUnESVUxOTBizszN NEn6SnIzPCCq MV3S[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NVXYbI1ROjF7MUK2NlA>
PC-3 NEmzZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnBNVAh|ryP M{O2fGlv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnjpZol1cW:wIHnuJINwdG:weTDmc5Ju[XSrb39CpC=> MWKyNVU4OTlzMh?=
EoL-1-cell MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KycGlEPTB;MT6wO|k5KM7:TR?= MVjTRW5ITVJ?
NCI-SNU-5 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjS[5dSUUN3ME2zMlEzQDRzIN88US=> M2PCW3NCVkeHUh?=
BV-173 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPIbXQ2UUN3ME21MlQ2PDB7IN88US=> NGT1V21USU6JRWK=
HCC1806 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTVwN{WxO|Mh|ryP M{TGVXNCVkeHUh?=
COLO-680 M{LRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jaVWlEPTB;Nj6yNVQxPiEQvF2= NHfPSJBUSU6JRWK=
HCC2218 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[wbohKSzVyPUeuO|k4ODRizszN NFv5Zo5USU6JRWK=
SK-MEL-24 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDlTWM2OD15LkixPVI1KM7:TR?= M2niOHNCVkeHUh?=
NCI-H720 M3HmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzOcpdKSzVyPUiuOFM3ODNizszN M{LnVXNCVkeHUh?=
KASUMI-1 M3vSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;Rd2lEPTB;OD64PVI3PiEQvF2= NHP4e3pUSU6JRWK=
HAL-01 M3nGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHQRYt3UUN3ME25Mlg5PjJizszN NVzJO3ZHW0GQR1XS
CAL-33 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m3SGlEPTB;MUCuOFM1KM7:TR?= MXPTRW5ITVJ?
SK-MEL-1 NEjuPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe5[nR1UUN3ME2xNk41PjZ|IN88US=> M1ixcHNCVkeHUh?=
Ramos-2G6-4C10 M3X0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF{LkS3OVIh|ryP NH;DUWVUSU6JRWK=
KY821 M3fCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF{LkS4OUDPxE1? NY[5dG9EW0GQR1XS
HEC-1 NW\keG04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF{LkmxPVYh|ryP MUTTRW5ITVJ?
SK-NEP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzYTWM2OD1zMz6xOlYh|ryP M1vtcXNCVkeHUh?=
MN-60 M1jHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfNPFZKSzVyPUGzMlU{QDlizszN MkDPV2FPT0WU
DU-145 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TsbmlEPTB;MUOuPVA2OyEQvF2= MWDTRW5ITVJ?
EW-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\4SppIUUN3ME2xOE42PTZ3IN88US=> NX;IXmpHW0GQR1XS
OS-RC-2 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF3Lkm1PFkh|ryP MljRV2FPT0WU
RPMI-8226 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHSNJkxUUN3ME2xOk4zODR{IN88US=> Mn60V2FPT0WU
ChaGo-K-1 M2GzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHWZ2ZKSzVyPUG2MlU{OjVizszN MlH3V2FPT0WU
DEL NVHBbm1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jIXmlEPTB;MU[uOlcyPyEQvF2= NXPpXm1zW0GQR1XS
GP5d MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknyTWM2OD1zNz6wOVMh|ryP MUTTRW5ITVJ?
COLO-668 M13hTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5TWM2OD1zNz62Nlk1KM7:TR?= NUSzWnVGW0GQR1XS
H9 M3TjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XYVmlEPTB;MUiuNlg{OyEQvF2= NWntSodGW0GQR1XS
NKM-1 NUfmcGNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDnb3VnUUN3ME2xPE42OTF7IN88US=> NH;v[2ZUSU6JRWK=
KYSE-150 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nlN2lEPTB;MUiuPVk5PiEQvF2= Mn;yV2FPT0WU
Daoy MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuzV|hKSzVyPUG5MlU3PDlizszN M3;lOXNCVkeHUh?=
ECC10 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\INGlEPTB;MkCuO|Q2PSEQvF2= NYrOenN1W0GQR1XS
A388 NHTyPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn61TWM2OD1{MT65NFkyKM7:TR?= M2TKNnNCVkeHUh?=
MHH-NB-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ|LkGzOlMh|ryP MUHTRW5ITVJ?
HCC1937 M{G0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7OUo9kUUN3ME2yOE44PDZizszN MnfKV2FPT0WU
TGBC11TKB M4P1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX60[FVlUUN3ME2yOU43QDZ|IN88US=> NWPvO|FDW0GQR1XS
CTV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPnU3FKSzVyPUK1Mlg6PjlizszN NUPFUY5DW0GQR1XS
NCI-H2029 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXMWnFKSzVyPUK2MlQzOzhizszN M{jmT3NCVkeHUh?=
HLE MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zBZmlEPTB;MkeuNFU1KM7:TR?= MUnTRW5ITVJ?
NCI-H1693 NVjSZWJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ5LkK4PVgh|ryP NWHpdVN7W0GQR1XS
HCC70 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfuUo1UUUN3ME2yO{44OjR4IN88US=> NHPXNlVUSU6JRWK=
BEN NHTtVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXRpJKSzVyPUK3Mlk2PjZizszN MoXZV2FPT0WU
LB771 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjQeYNKSzVyPUK4Mlg{PzNizszN NIXjRndUSU6JRWK=
697 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ7LkCyN|Uh|ryP MYrTRW5ITVJ?
LU-139 M4rqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnETWM2OD1{OT6zO|Q5KM7:TR?= MULTRW5ITVJ?
EW-13 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzR[o1KSzVyPUK5MlM5OTRizszN MmP4V2FPT0WU
MOLT-13 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLZem1KSzVyPUK5MlM5OTRizszN Mnm3V2FPT0WU
L-363 NGHvblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHVTWM2OD1{OT60O|k5KM7:TR?= MoWxV2FPT0WU
EM-2 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXJTWM2OD1{OT60PVAyKM7:TR?= NXfvVVRCW0GQR1XS
RS4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNyLkSyOFEh|ryP NIXON2RUSU6JRWK=
A2780 NIfI[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf6V29wUUN3ME2zNE44PDV5IN88US=> MmDmV2FPT0WU
KU812 M3;4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrBfY1oUUN3ME2zNk4{PjR{IN88US=> MlzrV2FPT0WU
COLO-684 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i0dGlEPTB;M{OuN|U6QSEQvF2= NWKyOW46W0GQR1XS
MFE-280 NULXVYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M176SGlEPTB;M{OuN|g5QSEQvF2= MXjTRW5ITVJ?
KG-1 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7CTWM2OD1|Mz62NFAyKM7:TR?= NGHlVZJUSU6JRWK=
JVM-3 NFrheIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN3LkW4Olgh|ryP M2Ts[nNCVkeHUh?=
MV-4-11 MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u2Z2lEPTB;M{WuPFQ6QSEQvF2= NIrOVoRUSU6JRWK=
LAMA-84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m3fGlEPTB;M{[uO|M1PSEQvF2= M{fWWnNCVkeHUh?=
MOLT-16 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq4PFlKSzVyPUO2Mlk2OiEQvF2= Ml;zV2FPT0WU
H4 NULoOHpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLl[ZdEUUN3ME2zO{42PjdizszN NF\2bpBUSU6JRWK=
T47D NIK0ZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL0R3EzUUN3ME2zO{44ODF6IN88US=> NYHHTXpPW0GQR1XS
CAL-54 M2rSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPtb4E2UUN3ME2zO{46PjZizszN MVLTRW5ITVJ?
SW982 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\PbpBKSzVyPUO4MlA6QThizszN MlPmV2FPT0WU
IGROV-1 M2H2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zw[WlEPTB;M{muN|MxPCEQvF2= MXnTRW5ITVJ?
NB14 NWTpbGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLRdJRNUUN3ME20NE44ODNzIN88US=> MkXaV2FPT0WU
HCC1187 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmwZ5QzUUN3ME20NU4zPzdzIN88US=> M3\qO3NCVkeHUh?=
SBC-1 NG\xV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[2UmlEPTB;NEGuN|A3OyEQvF2= M2\1UHNCVkeHUh?=
KARPAS-45 MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPVTWM2OD12MT60PFE5KM7:TR?= NG\qUlhUSU6JRWK=
MOLT-4 NXni[ol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[0fmlEPTB;NEKuNlU{QCEQvF2= M4\yeHNCVkeHUh?=
JVM-2 NXSzS49FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTR{LkmyNFch|ryP MoS2V2FPT0WU
A4-Fuk MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXEXI57UUN3ME20N{42PjlzIN88US=> NFzWeY9USU6JRWK=
MDA-MB-361 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR|Lki0NVQh|ryP M{ezcnNCVkeHUh?=
BALL-1 NVe3VotuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\FTWM2OD12Mz65OVMzKM7:TR?= Mnn1V2FPT0WU
T98G MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\XemJKSzVyPUS0Mlg2OTdizszN MkPPV2FPT0WU
Mo-T Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfCTWM2OD12NT62N|g6KM7:TR?= M4fJSnNCVkeHUh?=
MHH-PREB-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTR3Lke1PFUh|ryP NIDLPJRUSU6JRWK=
ALL-PO NEC4fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXThNHRWUUN3ME20O{4{PzlzIN88US=> NHfiUmZUSU6JRWK=
NCI-H510A M3;0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;lVGlEPTB;NEeuPVA{PCEQvF2= NHLzdpBUSU6JRWK=
ML-2 NIHEO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnjWXc1UUN3ME20PU44QDV4IN88US=> NX\jc4RMW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
体内研究 ABT-888推迟NCI-H460 移植瘤模型的肿瘤生长。ABT-888在B16F10 和9L 移植瘤模型中抑制PARP,从而增强temozolomide的抗癌活性。[1]ABT-888和其他细胞毒素药剂联用作用于MX-1移植瘤模型时显示出强抗癌效力。[2]在A375和 Colo829移植瘤模型中按肿瘤大小,每千克分别加3和12.5 mg ABT-888,可以看到肿瘤内95%以上PAR被抑制。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外PARP实验:

在含有50 mM Tris (pH 为8.0), 1 mM DTT,和 4 mM MgCl2的缓冲溶液中进行酶活性测定。PARP反应包含1.5 μM [3H]-NAD+ (1.6 μCi/mmol), 200 nM 生物素组蛋白 H1, 200 nM slDNA,及1 nM PARP-1或4 nM PARP-2酶。在加有100 μL 反应液的 96孔板上进行SPA检测。在50 μL含有PARP和DNA的2×酶液混合物中加入50 μL 2×NAD+基底混合物,反应开始。加入150 μL 1.5 mM 苯甲酰胺反应停止。170uL反应终止液转移到链霉亲和素包被的闪熔镀层上,温育1小时,用微型板块闪烁计数器计数。
细胞实验:[2]
- 合并
  • Cell lines: C41细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 0.5小时
  • Method: 在96孔板上用ABT-888处理C41细胞0.5小时。用1 mM H2O2破坏DNA10分钟,PARP被激活。用冰冻的PBS冲洗细胞,然后用预冷的甲醇/丙酮(按7:3比例混合)在−20oC下固定10 分钟。风干后,用PBS再溶解,然后用溶有5%脱脂奶粉的PBS- Tween封闭液(0.05%)在室温下阻断0.5小时。细胞和PAR抗体按1:50比例在封闭液中室温下温育1小时,然后用PBS-Tween-20冲洗5分钟,然后加入荧光素-5(6)-异硫氰酸酯 (FITC)-联用的二抗和1μg/mL DAPI封闭液中室温下温育1小时。PBS-Tween-20冲洗5分钟后,用荧光微型版计数器分析数据。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带NCI-H460, H460, B16F10和9L移植瘤的C57BL/6鼠
  • Formulation: 在含0.9% NaCl溶液中配制,调节pH 为4.0
  • Dosages: 25或3.125 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
0.5% methylcellulose+0.2% Tween 80
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 244.29
化学式

C13H16N4O

CAS号 912444-00-9
储存条件 粉状
溶于溶剂
别名 NSC 737664

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1
NCT01445522 Completed Drug: ABT-888|Drug: Cyclophosphamide Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3 2008 Phase 1
NCT00649207 Completed Drug: ABT-888|Radiation: Whole Brain Radiation Therapy Brain Diseases|Brain Neoplasms|Central Nervous System Diseases|Neoplasm Metastasis|Nervous System Neoplasms AbbVie (prior sponsor Abbott)|AbbVie March 2008 Phase 1
NCT00553189 Completed Drug: ABT-888|Drug: Topotecan Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2007 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Veliparib (ABT-888) | Veliparib (ABT-888)供应商 | 采购Veliparib (ABT-888) | Veliparib (ABT-888)价格 | Veliparib (ABT-888)生产 | 订购Veliparib (ABT-888) | Veliparib (ABT-888)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID